Home
Statistics
Acknowledgment
Enquire
Keyword Search
Complex Search
Segment Search
Peptide Mapping
Browse On
Mode of delivery
Animal model
Origin/Source
Peptide Length
Similarity
BLAST Search
Smith-Waterman
General
Help or Guide
Data Submission
Curators
Developers
Contact Us
Browse result page of B3Pdb
The total number entries retrieved from this search are
507
, scroll left/right for detailed information.
B3pdbID
PEPTIDE NAME
PEPTIDE SEQUENCE (1-letter)
PEPTIDE SEQUENCE (3-letter)
N-TERMINAL MODIFICATION
C-TERMINAL MODIFICATION
CHEMICAL MODIFICATION
PEPTIDE LENGTH
PEPTIDE CONFORMATION
PEPTIDE NATURE
SOURCE/ORIGIN OF PEPTIDE
SMILES
CELL LINE
In vitro
CONCENTRATION
In vitro
METHOD
In vitro
RESULT
ANIMAL MODEL
In vivo
CONCENTRATION
In vivo
MODE OF DELIVERY
In vivo
METHOD
In vivo
RESULT
ACTION
TRANSPORT TYPE
SUBCELLULAR LOCALISATION
COMBINATION
PHYSICAL CONDITION
RESPONSE
RESULT
LABEL
PMID
b3pdb_1150
Beauvericin
NA
NA
NA
NA
NA
6
Linear
NA
Chemically synthesized
NA
NA
NA
Efflux study ICU
NA
NA
NA
NA
NA
NA
NA
Permeability
NA
NA
NA
Brain elemination rate constant
-0.1205 min-1
Direct iodination
27349679
b3pdb_1151
Beauvericin
NA
NA
NA
NA
NA
6
Linear
NA
Chemically synthesized
NA
NA
NA
Capillary depletion
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
% parenchyma
91.92%
Direct iodination
27349679
b3pdb_1152
Beauvericin
NA
NA
NA
NA
NA
6
Linear
NA
Chemically synthesized
NA
NA
NA
Capillary depletion
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
% parenchyma
8.08%
Direct iodination
27349679
b3pdb_1153
Beauvericin
NA
NA
NA
NA
NA
6
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
Unidirectional influx rate constant
0.01115 mL/(g x min)
Direct iodination
27349679
b3pdb_1154
Beauvericin
NA
NA
NA
NA
NA
6
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
Initial disrobution volume
0.02191 ml/g
Direct iodination
27349679
b3pdb_1155
PepH1
VQQLTKRFSL
ValGlnGlnLeuThrLysArgPheSerLeu
NA
NA
NA
10
Linear
NA
Chemically synthesized
N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
NA
NA
Initial concentration in donor chamber-Culture
NA
NA
NA
NA
NA
NA
NA
Permeability
NA
NA
NA
Translocated
73.83%
99mTc(CO)3+
28263555
b3pdb_1156
PepH1
VQQLTKRFSL
ValGlnGlnLeuThrLysArgPheSerLeu
NA
NA
NA
10
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
% injected dose
0.02 %/g
99mTc(CO)3+
28263555
b3pdb_1164
MEL1201
H-YPW-(Ph)Map-NH2
H-Tyr-Pro-Trp-(Ph)Map-NH2
NA
NA
NA
3
Linear
NA
Chemically synthesized
NA
NA
NA
anti-nociception
NA
NA
NA
NA
NA
NA
NA
Permeability
NA
NA
NA
ED50
5.32 mg/kg
NA
26116761
b3pdb_1165
MEL1209
H-YPW-(3-ClPh)Map-NH2
H-Tyr-Pro-Trp-(3-ClPh)Map-NH2
NA
NA
NA
3
Linear
NA
Chemically synthesized
NA
NA
NA
anti-nociception
NA
NA
NA
NA
NA
NA
NA
Permeability
NA
NA
NA
ED50
28.58 mg/kg
NA
26116761
b3pdb_1166
MEL1214
H-YPW-(2-furyl)Map-NH2
H-Tyr-Pro-Trp-(2-furyl)Map-NH2
NA
NA
NA
3
Linear
NA
Chemically synthesized
NA
NA
NA
anti-nociception
NA
NA
NA
NA
NA
NA
NA
Permeability
NA
NA
NA
ED50
3.14 mg/kg
NA
26116761
b3pdb_1167
MEL1224
H-YPW-(2-furyl)Map-NH2
H-Tyr-Pro-Trp-(3-furyl)Map-NH2
NA
NA
NA
3
Linear
NA
Chemically synthesized
NA
NA
NA
anti-nociception
NA
NA
NA
NA
NA
NA
NA
Permeability
NA
NA
NA
ED50
4.02 mg/kg
NA
26116761
b3pdb_1168
PepNeg
SGTQEEY
Ser-Gly-Thr-Gln-Glu-Glu-Tyr
NA
NA
NA
7
Linear
NA
Chemically synthesized
NA
NA
NA
Initial concentration in donor chamber-Culture
NA
NA
NA
NA
NA
NA
NA
Permeability
NA
NA
NA
Translocated
42.50%
NA
29057814
b3pdb_1169
C-36
cKFFD
Dmt-c[D-Lys-Phe-Phe-Asp]NH2
NA
NA
NA
4
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
b3pdb_1170
F-81
NA
Dmt-c[D-Lys-Phe-p-CF3-Phe-Asp]NH2
NA
NA
NA
4
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
b3pdb_1171
LLVV-H4
LLVVYPWT
Leu-Leu-Val-Val-Tyr-Pro-Trp-Thr
NA
NA
NA
8
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
b3pdb_1172
LVV-H4
LVVYPWT
Leu-Val-Val-Tyr-Pro-Trp-Thr
NA
NA
NA
7
Linear
NA
Chemically synthesized
NA
NA
NA
Initial concentration in donor chamber-Culture
NA
NA
NA
NA
NA
NA
NA
Permeability
NA
NA
NA
Area
3.2 Counts
NA
29692758
b3pdb_1179
RD2D3
PTLHTHNRRRRRRPRTRLHTHRNR
Pro-Thr-Leu-His-Thr-His-Asn-Arg-Arg-Arg-Arg-Arg-Arg-Pro-Arg-Thr-Arg-Leu-His-Thr-His-Arg-Asn-Arg
NA
NA
NA
24
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
Brain to plasma ratio
0.6
H3/C14
27086111
b3pdb_1180
RD2D3
PTLHTHNRRRRRRPRTRLHTHRNR
Pro-Thr-Leu-His-Thr-His-Asn-Arg-Arg-Arg-Arg-Arg-Arg-Pro-Arg-Thr-Arg-Leu-His-Thr-His-Arg-Asn-Arg
NA
NA
NA
24
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
Peak response
0.3 µL/(g x min)
H3/C14
27086111
b3pdb_1181
RD2D3
PTLHTHNRRRRRRPRTRLHTHRNR
Pro-Thr-Leu-His-Thr-His-Asn-Arg-Arg-Arg-Arg-Arg-Arg-Pro-Arg-Thr-Arg-Leu-His-Thr-His-Arg-Asn-Arg
NA
NA
NA
24
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
Unidirectional influx rate constant
0.0003 ml/(g x min)
H3/C14
27086111
b3pdb_1182
RD2D3
PTLHTHNRRRRRRPRTRLHTHRNR
Pro-Thr-Leu-His-Thr-His-Asn-Arg-Arg-Arg-Arg-Arg-Arg-Pro-Arg-Thr-Arg-Leu-His-Thr-His-Arg-Asn-Arg
NA
NA
NA
24
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
Initial disrobution volume
0.0512 ml/g
H3/C14
27086111
b3pdb_1183
cRD2D3
PTLHTHNRRRRRRPRTRLHTHRNR
Pro-Thr-Leu-His-Thr-His-Asn-Arg-Arg-Arg-Arg-Arg-Arg-Pro-Arg-Thr-Arg-Leu-His-Thr-His-Arg-Asn-Arg
NA
NA
NA
24
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
Peak response
2 µL/(g x min)
H3/C14
29225107
b3pdb_1184
cRD2D3
PTLHTHNRRRRRRPRTRLHTHRNR
Pro-Thr-Leu-His-Thr-His-Asn-Arg-Arg-Arg-Arg-Arg-Arg-Pro-Arg-Thr-Arg-Leu-His-Thr-His-Arg-Asn-Arg
NA
NA
NA
24
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
Unidirectional influx rate constant
0.002 ml/(g x min)
H3/C14
29225107
b3pdb_1185
cRD2D3
PTLHTHNRRRRRRPRTRLHTHRNR
Pro-Thr-Leu-His-Thr-His-Asn-Arg-Arg-Arg-Arg-Arg-Arg-Pro-Arg-Thr-Arg-Leu-His-Thr-His-Arg-Asn-Arg
NA
NA
NA
24
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
Initial disrobution volume
0.1955 ml/g
H3/C14
29225107
b3pdb_1186
AH-D
SGSWLRDVWDWICTVLTDFKTWLQSKL
Ser-Gly-Ser-Trp-Leu-Arg-Asp-Val-Trp-Asp-Trp-Ile-Cys-Thr-Val-Leu-Thr-Asp-Phe-Lys-Thr-Trp-Leu-Gln-Ser-Lys-Leu
NA
NA
NA
27
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
Unidirectional influx rate constant
0.0003853 mL/(g x min)
NA
30349030
b3pdb_1187
AH-D
SGSWLRDVWDWICTVLTDFKTWLQSKL
Ser-Gly-Ser-Trp-Leu-Arg-Asp-Val-Trp-Asp-Trp-Ile-Cys-Thr-Val-Leu-Thr-Asp-Phe-Lys-Thr-Trp-Leu-Gln-Ser-Lys-Leu
NA
NA
NA
27
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
Initial disrobution volume
0.0060268 ml/g
NA
30349030
b3pdb_1188
NT2
Cav-RPYIL
Cav-Arg-Pro-Tyr-Ile-Leu
NA
NA
NA
6
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
PAMPA
NA
NA
NA
Permeability
NA
NA
NA
Translocated
85%
NA
30374780
b3pdb_1189
NT4
R-Cav-PYIL
Arg-Cav-Pro-Tyr-Ile-Leu
NA
NA
NA
6
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
PAMPA
NA
NA
NA
Permeability
NA
NA
NA
Translocated
90%
NA
30374780
b3pdb_1190
Macrocyclic inhibito
cGflGGrrrGfGGIGGc
Cys-Gly-Phe-Leu-Gly-Gly-Arg-Arg-Arg-Gly-Phe-Gly-Gly-Ile-Gly-Gly-Cys
NA
NA
NA
17
Linear
NA
Chemically synthesized
NA
NA
NA
Initial concentration in donor chamber-Culture
NA
NA
NA
NA
NA
NA
NA
Permeability
NA
NA
NA
Parallel artificial membrane permeation assay apparent permiability cofficient
14.6 cm/s
Fluorescent label
29908130
b3pdb_1191
Gly-Pro
GP
Gly-Pro
NA
NA
NA
2
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
in situ brain perfusion
NA
NA
NA
Permeability
NA
NA
NA
Unidirectional flux rate constant
0.00349 mL/(g x min)
NA
30962462
b3pdb_1192
Gly-Pro
GP
Gly-Pro
NA
NA
NA
2
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
in situ brain perfusion
NA
NA
NA
Permeability
NA
NA
NA
Brain/perfusate ratio
10.9
NA
30962462
b3pdb_1193
Tyr-Pro
TP
Tyr-Pro
NA
NA
NA
2
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
in situ brain perfusion
NA
NA
NA
Permeability
NA
NA
NA
Unidirectional flux rate constant
0.00353 mL/(g x min)
NA
30962462
b3pdb_1194
Tyr-Pro
TP
Tyr-Pro
NA
NA
NA
2
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
in situ brain perfusion
NA
NA
NA
Permeability
NA
NA
NA
Brain/perfusate ratio
10.5
NA
30962462
b3pdb_1195
mouse Des-octanoyl G
GSSFLSPEHQKAQQRKESKKPPAKLQPR
Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg
NA
NA
NA
28
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
Unidirectional influx rate constant
0.0002606 mL/(g x min)
Direct iodination
30293893
b3pdb_1196
mouse Des-octanoyl G
GSSFLSPEHQKAQQRKESKKPPAKLQPR
Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg
NA
NA
NA
28
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
Initial disrobution volume
0.002265 ml/g
Direct iodination
30293893
b3pdb_1197
ANK6
RKRIRLVTKKKR
Arg-Lys-Arg-Ile-Arg-Leu-Val-Thr-Lys-Lys-Lys-Arg
NA
NA
NA
12
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
Peak response
0.3 µL/(g x min)
H3/C14
29966196
b3pdb_1198
ANK6
RKRIRLVTKKKR
Arg-Lys-Arg-Ile-Arg-Leu-Val-Thr-Lys-Lys-Lys-Arg
NA
NA
NA
12
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
Unidirectional influx rate constant
0.0003 mL/(g x min)
H3/C14
29966196
b3pdb_1199
ANK6
RKRIRLVTKKKR
Arg-Lys-Arg-Ile-Arg-Leu-Val-Thr-Lys-Lys-Lys-Arg
NA
NA
NA
12
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
Initial disrobution volume
0.0575 ml/g
H3/C14
29966196
b3pdb_1203
cANK6r
RKRIRLVTKKKRR
Arg-Lys-Arg-Ile-Arg-Leu-Val-Thr-Lys-Lys-Lys-Arg-Arg
NA
NA
NA
13
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
Peak response
0.3 µL/(g x min)
H3/C14
29966196
b3pdb_1204
PEP inhibitory pepti
PPL
Pro-Pro-Leu
NA
NA
NA
3
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
Unidirectional influx rate constant
0.0003 mL/(g x min)
H3/C14
29966196
b3pdb_1205
OP5
NFDVLTEQ
Asn - Phe - Asp - Val - Leu - Thr - Glu - Gln
NA
NA
NA
8
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
Unidirectional influx rate constant
0.0396 ml/g
H3/C14
29966196
b3pdb_1206
SLSHSPQ
SLSHSPQ
Ser - Leu - Ser - His - Ser - Pro - Gln
NA
NA
NA
7
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
b3pdb_1207
NTGSPYE
NTGSPYE
Asn - Thr - Gly - Ser - Pro - Tyr - Glu
NA
NA
NA
7
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
b3pdb_1209
Penetratin
RQIKIWFQNRRMKWKK
NA
NA
NA
NA
16
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
Male Sprague-Dawley rats
2.0 mM
Intranasal
ELISA
L-penetratin increased the systemic absorption of leptin after intranasal administration.
The intranasal coadministration with L-penetratin could deliver leptin to the brain and in particula
Permeability
Hypothalamus
Combined with leptin
Obesity
NA
The intranasal coadministration with L-penetratin has a potential to deliver leptin into the therape
NA
31926192
b3pdb_1210
PHT-TGN-HBc
TGNYKALHPHNG
NA
NA
NA
NA
12
Linear
NA
Chemically synthesized
NA
Human astrocytes HA1800
0.2 mg PHT/kg
Confocal Microscopy
NA
Mice
0.2 mg PHT/kg
Intravenous
VIS Lumina II Spectrum Imaging System
It demonstrated high penetration ability
PHT-TGN-HBc NCs showed high antiepileptic effects in epilepsy mouse model with no side effects
Permeability
Cerebral vasculature
Comined with phenytoin and hepatitis B core
Refractory Epilepsy
It prolongs the circulation time of the drug and efficiently load large amount of drugs, and showed
It efficiently target the brain tissue by 2.4 fold and increase the antiepileptic efficiency of phen
NA
32087458
b3pdb_1211
P15
VQITYK
NA
N-terminal acetylation
C-terminal amidation
NA
6
Linear
NA
Chemically synthesized
NA
Human brain endothelial cells (EA.hy926)
NA
Field-emission transmission electron microscope
A3 peptide treated with this peptide, showed higher folds of decrease in fluorescence intensities a
NA
NA
NA
NA
NA
Trojan peptides are capable of translo- cating the BBB, without affecting its interity.
Translocation
NA
Comined with A3 pepide
Tauopathies
These peptides were capable of reducing the tau elicit toxicity by accelerating or impeding the self
These peptide-based modulators (Trojans) were non-amyloidogenic, stable in serum and showed minimal
NA
32114026
b3pdb_1212
P16
VQILYK
NA
N-terminal acetylation
C-terminal amidation
NA
6
Linear
NA
Chemically synthesized
NA
Human brain endothelial cells (EA.hy926)
NA
Field-emission transmission electron microscope
A3 peptide treated with this peptide, showed higher folds of decrease in fluorescence intensities a
NA
NA
NA
NA
NA
Trojan peptides are capable of translo- cating the BBB, without affecting its interity.
Translocation
NA
Comined with A3 pepide
Tauopathies
These peptides were capable of reducing the tau elicit toxicity by accelerating or impeding the self
These peptide-based modulators (Trojans) were non-amyloidogenic, stable in serum and showed minimal
NA
32114026
b3pdb_1213
P17
VQIIYK
NA
N-terminal acetylation
C-terminal amidation
NA
6
Linear
NA
Chemically synthesized
NA
Human brain endothelial cells (EA.hy926)
NA
Field-emission transmission electron microscope
A3 peptide treated with this peptide, showed higher folds of decrease in fluorescence intensities a
NA
NA
NA
NA
NA
Trojan peptides are capable of translo- cating the BBB, without affecting its interity.
Translocation
NA
Comined with A3 pepide
Tauopathies
These peptides were capable of reducing the tau elicit toxicity by accelerating or impeding the self
These peptide-based modulators (Trojans) were non-amyloidogenic, stable in serum and showed minimal
NA
32114026
b3pdb_1214
P18
VQIVYK
NA
NA
C-terminal amidation
NA
6
Linear
NA
Chemically synthesized
NA
Human brain endothelial cells (EA.hy926)
NA
Field-emission transmission electron microscope
A3 peptide treated with this peptide, showed higher folds of decrease in fluorescence intensities a
NA
NA
NA
NA
NA
Trojan peptides are capable of translo- cating the BBB, without affecting its interity.
Translocation
NA
Comined with A3 pepide
Tauopathies
These peptides were capable of reducing the tau elicit toxicity by accelerating or impeding the self
These peptide-based modulators (Trojans) were non-amyloidogenic, stable in serum and showed minimal
NA
32114026
b3pdb_1215
P19
VQILYK
NA
NA
C-terminal amidation
NA
6
Linear
NA
Chemically synthesized
NA
Human brain endothelial cells (EA.hy926)
NA
Field-emission transmission electron microscope
A3 peptide treated with this peptide, showed higher folds of decrease in fluorescence intensities a
NA
NA
NA
NA
NA
Trojan peptides are capable of translo- cating the BBB, without affecting its interity.
Translocation
NA
Comined with A3 pepide
Tauopathies
These peptides were capable of reducing the tau elicit toxicity by accelerating or impeding the self
These peptide-based modulators (Trojans) were non-amyloidogenic, stable in serum and showed minimal
NA
32114026
b3pdb_1216
P20
VQIYK
NA
NA
C-terminal amidation
NA
6
Linear
NA
Chemically synthesized
NA
Human brain endothelial cells (EA.hy926)
NA
Field-emission transmission electron microscope
A3 peptide treated with this peptide, showed higher folds of decrease in fluorescence intensities a
NA
NA
NA
NA
NA
Trojan peptides are capable of translo- cating the BBB, without affecting its interity.
Translocation
NA
Comined with A3 pepide
Tauopathies
These peptides were capable of reducing the tau elicit toxicity by accelerating or impeding the self
These peptide-based modulators (Trojans) were non-amyloidogenic, stable in serum and showed minimal
NA
32114026
previous
1
2
3
4
5
6
7
8
9
10
11
next
IIITD/CB
Raghava's Group
IMTECH
CellPPDMOD